Osborne Clarke has advised RHYTHM AI, a UK company focused on the treatment of Atrial Fibrillation, on the closure of a £2.15m seed financing round. AF…
Standard 1 Year Membership Required
You must be a Standard 1 Year member to access this content.
Already a member? Log in here
